# Nuclide record enza-p (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/enza-p/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "enza-p", "NCT04419402" ;
  schema:name "ENZA-p"@en ;
  schema:alternateName "ANZUP 1901"@en ;
  schema:description "Adding the radioactive drug lutetium-PSMA to the hormone drug enzalutamide, with the dose adjusted according to a mid-treatment PET scan, kept prostate cancer under control for longer and helped men with high-risk metastatic disease live longer than enzalutamide on its own."@en ;
  schema:url <https://nuclide.cc/trials/enza-p/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00135-9/abstract>, <https://pubmed.ncbi.nlm.nih.gov/39956124/>, <https://clinicaltrials.gov/study/NCT04419402> ;
  nuclide:status "active" ;
  nuclide:tag "radioligand therapy", "prostate cancer", "combination therapy", "adaptive dosing" ;
  nuclide:phase "2" ;
  nuclide:related <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/drugs/enzalutamide/>, <https://nuclide.cc/indications/prostate-mcrpc/>, <https://nuclide.cc/technologies/psma-pet/>, <https://nuclide.cc/trials/psmafore/>, <https://nuclide.cc/isotopes/lu-177/> .